The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Identification of the principal proteoglycan-binding site in LDL. A single-point mutation in apo-B100 severely affects proteoglycan interaction without affecting LDL receptor binding.
Open accessAbstract
The subendothelial retention of LDLs through their interaction with proteoglycans has been proposed to be a key process in the pathogenesis of atherosclerosis. In vitro studies have identified eight clusters of basic amino acids in delipidated apo-B100, the protein moiety of LDL, that bind the negatively charged proteoglycans. To determine which of these sites is functional on the surface of LDL particles, we analyzed the proteoglycan-binding activity of recombinant human LDL isolated from transgenic mice. Substitution of neutral amino acids for the basic amino acids residues in site B (residues 3359-3369) abolished both the receptor-binding and the proteoglycan-binding activities of the recombinant LDL. Chemical modification of the remaining basic residues caused only a marginal further reduction in proteoglycan binding, indicating that site B is the primary proteoglycan-binding site of LDL. Although site B was essential for normal receptor-binding and proteoglycan-binding activities, these activities could be separated in recombinant LDL containing single-point mutation. Recombinant LDL with a K3363E mutation, in which a glutamic acid had been inserted into the basic cluster RKR in site B, had normal receptor binding but interacted defectively with proteoglycans; in contrast, another mutant LDL, R3500Q, displayed defective receptor binding but interacted normally with proteoglycans. LDL with normal receptor-binding activity but with severely impaired proteoglycan binding will be a unique resource for analyzing the importance of LDL- proteoglycan interaction in atherogenesis. If the subendothelial retention of LDL by proteoglycans is the initial event in early atherosclerosis, then LDL with defective proteoglycan binding may have little or no atherogenic potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Response-to-Retention Hypothesis of Early Atherogenesis
Williams, K. J., & Tabas, I. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.5.551 · Cited by 1,413
Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes
Jackson, R. L., Busch, S. J., & Cardin, A. D. (1991) · Physiological Reviews · doi:10.1152/physrev.1991.71.2.481 · Cited by 1,094
Basu, S. K., Goldstein, J. L., Anderson, G. W., & Brown, M. S. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.9.3178 · Cited by 1,021
Cell Biology of Atherosclerosis
Ross, R. (1995) · Annual Review of Physiology · doi:10.1146/annurev.ph.57.030195.004043 · Cited by 1,003
Weisgraber, K. H., Innerarity, T. L., & Mahley, R. W. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34284-9 · Cited by 618
Self-citationRelease of low density lipoprotein from its cell surface receptor by sulfated glycosaminoglycans
Goldstein, J. L., Basu, S. K., Brunschede, G. Y., & Brown, M. S. (1976) · Cell · doi:10.1016/0092-8674(76)90258-0 · Cited by 613
Mahley, R. W., Innerarity, T. L., Pitas, R. E., Weisgraber, K. H., Brown, J. H., & Gross, E. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)66966-8 · Cited by 383
Self-citationSchönherr, E., Järveläinen, H. T., Sandell, L. J., & Wight, T. N. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)47419-x · Cited by 334
Self-citationLinton, M. F., Farese, R. V., Chiesa, G., Grass, D. S., Chin, P., Hammer, R. E., Hobbs, H. H., & Young, S. G. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116927 · Cited by 246
Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3.
Weisgraber, K. H., Rall, S. C., Mahley, R. W., Milne, R. W., Marcel, Y. L., & Sparrow, J. T. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35898-2 · Cited by 240
Cited by
Lusis, A. J. (2000) · Nature · doi:10.1038/35025203 · Cited by 4,839
Role of Oxidative Modifications in Atherosclerosis
Stocker, R., & Keaney, J. F. (2004) · Physiological Reviews · doi:10.1152/physrev.00047.2003 · Cited by 2,624
Borén, J., Chapman, M. J., Krauss, R. M., Packard, C. J., Bentzon, J. F., Binder, C. J., Daemen, M. J., Demer, L. L., Hegele, R. A., Nicholls, S. J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz962 · Cited by 1,601
Self-citationTabas, I., Williams, K. J., & Borén, J. (2007) · Circulation · doi:10.1161/circulationaha.106.676890 · Cited by 1,399
Subendothelial retention of atherogenic lipoproteins in early atherosclerosis
Skålén, K., Gustafsson, M., Rydberg, E. K., Hultén, L. M., Wiklund, O., Innerarity, T. L., & Borén, J. (2002) · Nature · doi:10.1038/nature00804 · Cited by 1,019
“The interaction between atherogenic lipoproteins and proteoglycans involves an ionic interaction between basic amino acids in apoB100 and negatively charged sulphate groups on the proteoglycan”
BackgroundSelf-citationNapoli, C., Glass, C. K., Witztum, J. L., Deutsch, R., D'Armiento, F. P., & Palinski, W. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02131-5 · Cited by 645
Sandesara, P. B., Virani, S. S., Fazio, S., & Shapiro, M. D. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00184 · Cited by 608
Borén, J., & Williams, K. J. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000330 · Cited by 524
“In earliest atherogenesis, negatively charged proteoglycans in the extracellular matrix of the arterial intima bind and trap apoB-lipoproteins via electrostatic interactions with specific positively charged aminoacyl residues in the full-length hepatic form of apoB, apoB100 (residues 3359–3369) [32], and in the trunca…”
BackgroundSelf-citationStructure of apolipoprotein B-100 in low density lipoproteins
Segrest, J. P., Jones, M. K., De Loof, H., & Dashti, N. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30267-4 · Cited by 522
Hevonoja, T., Pentikäinen, M. O., Hyvönen, M. T., Kovanen, P. T., & Ala-Korpela, M. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(00)00123-2 · Cited by 436
The response‐to‐retention hypothesis of atherogenesis reinforced
Williams, K. J., & Tabas, I. (1998) · Current Opinion in Lipidology · doi:10.1097/00041433-199810000-00012 · Cited by 395
Proteoglycans in Atherosclerosis and Restenosis: Key Roles for Versican
Wight, T. N., & Merrilees, M. J. (2004) · Circulation Research · doi:10.1161/01.res.0000126921.29919.51 · Cited by 362
Self-citationPostprandial lipoprotein metabolism and atherosclerosis.
Karpe, F. (1999) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1999.00548.x · Cited by 360
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia
Borén, J., Taskinen, M.-R., Björnson, E., & Packard, C. J. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00676-y · Cited by 315
Self-citationBhakdi, S., Torzewski, M., Klouche, M., & Hemmes, M. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.10.2348 · Cited by 326
Paulson, K. E., Zhu, S.-N., Chen, M., Nurmohamed, S., Jongstra-Bilen, J., & Cybulsky, M. I. (2010) · Circulation Research · doi:10.1161/circresaha.109.210781 · Cited by 317
Apolipoproteins in vascular biology and atherosclerotic disease
Mehta, A., & Shapiro, M. D. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00613-5 · Cited by 273
Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target
Behbodikhah, J., Ahmed, S., Elyasi, A., Kasselman, L. J., De Leon, J., Glass, A. D., & Reiss, A. B. (2021) · Metabolites · doi:10.3390/metabo11100690 · Cited by 270
PALINSKI, W., & NAPOLI, C. (2002) · The FASEB Journal · doi:10.1096/fj.02-0226rev · Cited by 268
Brites, F., Martin, M., Guillas, I., & Kontush, A. (2017) · BBA Clinical · doi:10.1016/j.bbacli.2017.07.002 · Cited by 265
Öörni, K., Pentikäinen, M. O., Ala-Korpela, M., & Kovanen, P. T. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31964-7 · Cited by 252
Lipid disorders and mutations in the APOB gene
Whitfield, A. J., Barrett, P. H. R., van Bockxmeer, F. M., & Burnett, J. R. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.038026 · Cited by 243
From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk
Shapiro, M. D., & Fazio, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306471 · Cited by 217
Modified LDL – trigger of atherosclerosis and inflammation in the arterial intima
Pentikäinen, M. O., Öörni, K., Ala‐Korpela, M., & Kovanen, P. T. (2000) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2000.00655.x · Cited by 204
Do the Apoe −/− and Ldlr −/– Mice Yield the Same Insight on Atherogenesis?
Getz, G. S., & Reardon, C. A. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.306874 · Cited by 198
The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
Borén, J., Packard, C. J., & Taskinen, M.-R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00474 · Cited by 196
“This is mediated by ionic interactions between positively charged domains in apoB100 (74), and negatively charged artery wall proteoglycans (75).”
BackgroundSelf-citationPCSK9 and inflammation: a review of experimental and clinical evidence
Momtazi-Borojeni, A. A., Sabouri-Rad, S., Gotto, A. M., Pirro, M., Banach, M., Awan, Z., Barreto, G. E., & Sahebkar, A. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz022 · Cited by 188
How does the macula protect itself from oxidative stress?
Handa, J. T. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.03.006 · Cited by 154
Olin-Lewis, K., Krauss, R. M., La Belle, M., Blanche, P. J., Barrett, P. H. R., Wight, T. N., & Chait, A. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200322-jlr200 · Cited by 114
Self-citationTriglyceride-rich lipoproteins and remnants: targets for therapy?
Dallinga-Thie, G. M., Kroon, J., Borén, J., & Chapman, M. J. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0745-6 · Cited by 90
Self-citationMonogenic hypocholesterolaemic lipid disorders and apolipoprotein B metabolism
Hooper, A. J., van Bockxmeer, F. M., & Burnett, J. R. (2005) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360500295113 · Cited by 89
Lehti, S., Nguyen, S. D., Belevich, I., Vihinen, H., Heikkilä, H. M., Soliymani, R., Käkelä, R., Saksi, J., Jauhiainen, M., Grabowski, G. A., et al. (2018) · The American Journal of Pathology · doi:10.1016/j.ajpath.2017.09.019 · Cited by 79
Mechanism of lipoprotein retention by the extracellular matrix
Gustafsson, M., & Borén, J. (2004) · Current Opinion in Lipidology · doi:10.1097/00041433-200410000-00003 · Cited by 75
Self-citationModification of lipoprotein metabolism and function driving atherogenesis in diabetes
Luciani, L., Pedrelli, M., & Parini, P. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117545 · Cited by 72
Ishigaki, Y., Oikawa, S., Suzuki, T., Usui, S., Magoori, K., Kim, D.-H., Suzuki, H., Sasaki, J., Sasano, H., Okazaki, M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005906200 · Cited by 58
Apolipoproteins: New players in cancers
He, Y., Chen, J., Ma, Y., & Chen, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1051280 · Cited by 52
Heparan sulfate proteoglycans and triglyceride-rich lipoprotein metabolism
Bishop, J. R., Stanford, K. I., & Esko, J. D. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3282feec2d · Cited by 49
Glycosaminoglycan-lipoprotein interaction
Olsson, U., Östergren-Lundén, G., & Moses, J. (2001) · Glycoconjugate Journal · doi:10.1023/a:1021155518464 · Cited by 46
“Previous studies included the immobilization of GAGs on agarose beads [18], precipitation of lipoprotein-glycosaminoglycan complexes [19] or ELISA-based assays [ 15 ].”
Antiatherosclerotic Effect of an Antibody That Binds to Extracellular Matrix Glycosaminoglycans
Soto, Y., Acosta, E., Delgado, L., Pérez, A., Falcón, V., Bécquer, M. A., Fraga, Á., Brito, V., Álvarez, I., Griñán, T., et al. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.238659 · Cited by 41
Etiological significance of apolipoprotein E mutations in lipoprotein glomerulopathy
Saito, T., Ishigaki, Y., Oikawa, S., & Yamamoto, T. T. (2002) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(01)00148-7 · Cited by 25
Clinicopathological and genetic characteristics in Chinese patients with lipoprotein glomerulopathy
Zhang, B., Liu, Z.-H., Zeng, C.-H., Zheng, J.-M., Chen, H.-P., & Li, L.-S. (2008) · Journal of Nephrology · doi:10.1093/joneph/21.1.110 · Cited by 12
Metadata
- Authors
- Borén, J., Olin, K., Lee, I., Chait, A., Wight, T. N., & Innerarity, T. L.
- Venue
- Journal of Clinical Investigation
- Published
- 1998-06-15
- Volume
- 101
- Issue
- 12
- Pages
- 2658-2664
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2045868118
- Cited by
- 320
- References
- 43
- FWCI
- 17.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.